Morgan Stanley Xtl Biopharmaceuticals LTD Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Morgan Stanley holds 18,351 shares of XTLB stock, worth $23,489. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,351
Previous 26,451
30.62%
Holding current value
$23,489
Previous $63,000
44.44%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding XTLB
# of Institutions
5Shares Held
427KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$254,5760.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$254,5760.08% of portfolio
-
Rhumbline Advisers Boston, MA11KShares$14,0210.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $6.97M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...